UBS made no change to the firm’s Buy rating or $142 price target on DaVita after the company hosted management. The firm walked away from the meeting with increased comfort and a better understanding of the narrow scope that should be considered when considering the effects of GLP-1s on future ESRD patients and believes the impact from California wage laws won’t be as bad as feared, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DVA: